PBAC's latest decision on Ixazomib: Recommended with restriction (2022). Considered for Relapsed and/or refractory multiple myeloma (RRMM) after at least two prior therapies, in combination with lenalidomide and dexamethasone.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
—
ICER not stated
Submissions
2
first 2020
Submissions
2
2020 → 2022
Eligible population
Adults with histologically-confirmed multiple myeloma who have received at least two prior therapies, treated with ixazomib in combination with lenalidomide and dexamethasone.
Therapy area
Haematology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
PFS, OS, ORR
Key trials
TMM-1
Comparator
lenalidomide in combination with dexamethasone (Ld)
Economic model
CUA
ICER note
ICER value not stated in the public summary document; economic evaluation based on cost utility analysis versus Ld.
Submission history
Nov 2020: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Authority Required